Cytokinetics, Astellas expand in neuromuscular space

Cytokinetics Inc. (NASDAQ:CYTK) added $0.62 to (13%) $5.52 on news it will receive $55 million in payments from Astellas Pharma Inc. (Tokyo:4503) to expand their skeletal muscle activation collaboration into neuromuscular indications.

Under the expanded deal, the partners will develop CK-2127107, a fast skeletal muscle troponin activator, to treat spinal muscular atrophy (SMA) and potentially other neuromuscular indications. ...